Answers are grounded in this paper and cite their sources.
Next-gen urine tenofovir assay detects early non-adherence in HIV patients, suggesting females may require higher adherence for equivalent protection.
Abtract Accurate point-of-care tools are needed to detect early non-adherence to daily HIV regimens and support timely transitions to long-acting options. Emerging evidence suggests females may require higher adherence to achieve equivalent protection. Our next-gen urine tenofovir assay showed high accuracy across sexes, but lower urine drug levels among females.
No takes yet. Share an insight, caveat, or question.
Niu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: